Navigation Links
Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
Date:11/11/2008

sease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit http://www.ilgenetics.com.

Certain statements contained herein are "forward-looking" statements including statements regarding our ability to develop diagnostic, personalized nutritional and therapeutic products to prevent or treat diseases of inflammation and other genetic variations, our ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and our ability to make progress in advancing our core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of our products, the risk of technology and product obsolescence, delays in product development, the performance of our commercial partners, the availability of adequate capital, the actions of our competitors and other competitive risks, and those risks and uncertainties described in our annual reports on Form 10-K, our quarterly reports on Form 10-Q and other documents we file with, or furnish to, the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Interleukin Genetics Announces Management and Board Appointments
2. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
3. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
4. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
5. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
6. Interleukin Genetics Retains Top Life Science Communications Firms
7. Interleukin Genetics Announces Conference Call and Webcast to Discuss Fourth Quarter and Year End 2007 Business Results
8. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
10. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
11. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... 6 Calbiotech, Inc. announced toda...tive Research (SBIR) Phase I contract by the U.S. ...terms of the agreement, Calbiotech will develop an...f Dengue virus. ,, Dengue virus is a mosquit...o military forces deployed to tropical areas of th...
(Date:11/6/2009)...nda for Arrowhead’s 2010 Personalized Medici...lace on February 22-24, 2010 in Philadelphia, has ...ll highlight key issues in forming partnerships an...ces. , Minneapolis, MN (P...’s 2010 Personalized Medicine Partnerships ...
(Date:11/5/2009)...PRNewswire/ -- The endangered black-footed ferrets...is rare carnivore feeds on prairie dogs. The pra... entire population die-offs in towns occur. The U...ted a ferret breeding program and has been releasi...tive habitat. Unfortunately, plague can sweep thr...
(Date:11/5/2009).... 5 ThermoGenesis Corp. ... products for processing and storing adult stem ce...of fiscal 2010. ,, For the quarter ended Septem...2 million, a 15 percent increase over revenues of ...Company said the key contributors to the growth in...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...ioness Inc., an innovative provider of advanced ne...very from central nervous system disorders, announ...’s largest provider of inpatient rehabilitat...ity of the NESS H200 Hand Rehabilitation System an...bilitation hospitals nationwide. , ...
...RUG DEVELOPMENT, ROCKVILLE, Md., July 30 Stem ce...d that Dr. Thomas Hazel will be,rejoining the comp... be,working with Dr. Karl Johe, Neuralstem,s Chair...ny,s upcoming clinical trial for ALS,(Amytrophic L...mplete,development of Neuralstem,s small molecule ...
... Development Of Lead Drug Candidates, MARKHAM, ON...d the,closing of a CDN $45 million Series C financ...ubishi Tanabe Pharma Corporation ("MTPC"), and sup... Vengrowth Advanced Life,Sciences Fund Inc., Caiss...an Medical Discoveries Fund Inc., T(2)C(2)/Bio 200...
Other Biology Technology: Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Neuralstem Fills Key Product Development Position 2Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
(Date:11/8/2009)...ers at Purdue University have discovered a new app... cord injuries using nano-spheres that could be in..., The synthetic "copolymer micelles" are drug-del...roughly 100 times smaller than the diameter of a r...how to deliver drugs for cancer treatment and othe...
(Date:11/6/2009)...in harmony with their arboreal hosts. But new rese...heir trees of choice, the ants can get destructive... in the November issue of the American Naturalist...ve trees, and it reopens a centuries-old debate on...s and certain species of plants and trees have coz...
(Date:11/5/2009)...rded a training grant in the amount of $2,756,719 ...rative Graduation Education and Research Training ...be awarded to Kent State. The grant, which is fund...t of 2009, runs through 2014. , The grant funds ...ic resource sensing (EARS). The purpose of the pro...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 1Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 2Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 3Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 4Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 5Alcohol advertising self regulation not working as ads target younger drinkers 48311 1Alcohol advertising self regulation not working as ads target younger drinkers 48311 2Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 1Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 2
...the results are receiving rave reviews from apple ...nd research, a new apple cultivar has been introdu...ing program of the Illinois, New Jersey, and India...apple will be sold under the name ,WineCrisp,. Sch...urces and Environmental Sciences at the University...
...produce, which includes packaged lettuces, has gre...tbreaks associated with these products. To reduce ...s are used for decontamination once the food is ha...e fields is equally important. Researchers from th...f California, Davis and University of Arizona), le...
...tigators have uncovered a mechanism that helps exp...lar mood disorder, also protects the brain from da...n the May 1 issue of the Journal of Clinical Inve...how that lithium promotes DNA repair in healthy ce...gest that lithium treatment could offer a way to p...
Other Biology News:Apple enthusiasts welcome WineCrisp 2Protecting fresh-cut produce 2Lithium may help radiation target cancer, spare healthy tissue 2Lithium may help radiation target cancer, spare healthy tissue 3
...nity Life Sciences can provide custom microplate c...croplate processing equipment that dispenses and w...mmodate virtually any lot size of the following fo... 8 and 12 well strips, 96 well microplate, ...
Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter
Mynox Mycoplasma Elimination Reagent from Minerva Biolabs GmbH
Mynox Mycoplasma Elimination Reagent from Sigma-Aldrich
Biology Products: